Inhibrx Biosciences, Inc.

Inhibrx, Inc.

Regeneron Pharmaceuticals, Inc.

Lucas Rascon

Brendan P Eckelman

John C Timmer

Quinn L Deveraux

Amir S Razai

Abrahim Hussain

Rajay A Pandit

Mike Kaplan

Kyle S Jones

Bryan Becklund

Chelsie Macedo

Angelica N Sanabria

Chelsie Hata

Jordan Jarjour

Mark Pogson

Wai-hang Leung

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

CLL-1 targeted immunotherapies

This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.

Multivalent and multispecific OX40-binding fusion proteins

This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.

Multivalent and multispecific 41BB-binding proteins

Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.

CLEC12a binding polypeptides and uses thereof

PDL1-binding proteins

Multivalent and multispecific 41BB-binding fusion proteins

Growing community of inventors

La Jolla, CA, United States of America

Lucas Rascon